

フォーラムの成果***

—産から—

春日 芳 朋***

**Achievements of the Forum for Anticancer Drug Development
from an Industry Perspective*****

Yoshitomo KASUGA***

Summary

This article summarises, from the perspective of the pharmaceutical industry, the role that the Forum for Anticancer Drug Development has played in promoting anti-cancer drug development. In relation to the main themes of each forum, i.e., revised anticancer drug guidelines, promotion of multinational clinical studies, establishment of infrastructure for promotion of clinical studies, and best practice for post-marketing surveillance and studies, we first sought opinions among members from industry, government and academia, and then we sought further opinions from representatives of each of the companies affiliated with the Anticancer Drug Development Taskforce of the Technical Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) concerning the topics for which further discussions are needed. At the same time, we conducted a survey of participation in multinational clinical studies by each of the affiliated companies. It was found that topics such as dealing with ethnic differences and handling coadministered drugs when conducting multinational clinical studies need further discussion. It was also found that there is a trend towards participation from Japan in a greater number of multinational clinical studies of anticancer drugs. The Forum for Anticancer Drug Development has fulfilled its function of encouraging active participation in multinational clinical studies of anticancer drugs by hosting face-to-face discussions between representatives from industry, government and academia. It has also played an extremely important role by educating personnel involved in the development of the industry. We conclude that there are significant benefits to continuing its activities.

Key words

Oncology drug development, Multinational clinical study, Ethnic difference, Pharmaceutical industry perspective